DRKS00019021招募中不适用
Implementation of pharmacogenetic testing at the Robert-Bosch-Krankenhaus - IKP428
Robert Bosch Gesellschaft für medizinische Forschung mbH (RBMF)0 个研究点目标入组 100 人开始时间: 2020年3月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Adults aged 18 or older
- •Ability to give independent informed consent
- •Signed written informed consent
- •actual or planned prescription of at least one of the concerned drugs
排除标准
- •Inability to give independent informed consent
研究者
相似试验
尚未招募
不适用
Pharmacogenetic testing in the clinical setting: is screening for TPMT genotype a cost-effective treatment strategy? The first prospective randomized controlled trial within the Dutch health care system.Inflammatory Bowel DiseaseNL-OMON30092Zorgonderzoek Nederland (ZON)1,000
进行中（未招募）
1 期
Protocol for taking pharmacogenetic testing of tacrolimus into the clinical arena: patient tailored anti-rejection therapyEUCTR2006-005774-50-GBCentral Manchester & Manchester Children's University Hospitals NHS Trust400
已完成
4 期
Implementation of PPI Medication PGX TestingGastroesophageal RefluxNCT02794844Nemours Children's Clinic28
招募中
不适用
PREemptive pharmacogenomic testing for Preventing Adverse drug REactionsbijwerkingenAdverse drug reactionsNL-OMON50620eids Universitair Medisch Centrum1,450
进行中（未招募）
1 期
PREemptive Pharmacogenomic testing for Preventing Adverse drug REactions (PREPARE)Adverse drug reactionsEUCTR2016-003325-41-ATeiden University Medical Center